Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...

The TRAVERSE trial, a large-scale clinical study with over 5,000 patients, published in 2023, concluded that TRT does not increase the risk of adverse cardiovascular outcomes in men with hypogonadism.

BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has commended Nanomerics for the successful completion of a human ...